key: cord-1013206-6jplmcpp authors: Regan, Paul; Elkhalifa, Shuayb; Barratt, Paul title: The systemic immunosuppressive effects of peripheral corticosteroid injections: A narrative review of the evidence in the context of COVID‐19 date: 2021-12-09 journal: Musculoskeletal Care DOI: 10.1002/msc.1603 sha: 779e585c48d62bd20208811e96cd9d8da16a0e4f doc_id: 1013206 cord_uid: 6jplmcpp INTRODUCTION: Injected glucocorticoid's (corticosteroids) are commonly used in musculoskeletal practice. The current global COVID‐19 pandemic has increased attention on the potential for locally injected corticosteroids to exert a systemic immunosuppressive effect and the implications this may have in relation to COVID‐19 infection and vaccination. AIM: This narrative review summarises the evidence regarding the potential systemic immunosuppressive effects of peripheral corticosteroid injections in relation to the ongoing COVID‐19 pandemic. METHOD: A narrative review was selected to allow inclusion of evidence related to a diverse range of topics relevant to this subject in order to provide the most comprehensive and clinically relevant guidance for clinicians. RESULTS/DISCUSSION: Current evidence demonstrates that cytotoxic, phagocytic and antigen presenting cells involved in both the innate and adaptive immune responses are suppressed for 48 h post‐injection and messenger cytokines that are integral to immune function are suppressed for over 96 h post‐injection. This potentially reduces an individual's ability to prevent viral infection, limit early viral replication, and delays activation of adaptive immune mechanisms (T and B lymphocytes) and subsequent viral clearance and elimination. The hypothalamic–pituitary–adrenal (HPA) axis can be suppressed for 2–4 weeks or longer following peripheral corticosteroid injections. The role of the HPA axis in immune function is not fully understood, however this could potentially indicate longer lasting immunosuppression. CONCLUSIONS: This review found evidence of suppression of immune cell numbers for the first 48 h post‐injection, cytokines for over 96 h post‐injection and HPA axis suppression lasting for 2–4 weeks or longer. There is currently no evidence that these physiological changes translate into a clinically meaningful increased risk of COVID‐19 infection or related morbidity or mortality, but there is also no persuasive evidence that they do not. This review discusses the implications of the current evidence in relation to shared decision making, informed consent, risk management and COVID‐19 vaccination to provide clinicians with a pragmatic guide to help navigate the current uncertainty regarding the potential immunosuppressive effects of peripheral corticosteroid injections. Injection of exogenous glucocorticoids (commonly termed corticosteroids) has been part of musculoskeletal and rheumatological practice for over 50 years (Cole & Schumacher, 2005) . It is well established that oral corticosteroids exert a systemic immunosuppressive effect (Hoes et al., 2009; Stuck et al., 1989; Youseff et al., 2016) , and that locally injected corticosteroids can exert a local immunosuppressive effect (Kaspar & De Beer, 2005; Marsland et al., 2014; McIntosh et al., 2006) . However, the systemic immunosuppressive effects of locally injected corticosteroids are less clear. Health Service, 2020). This prompted a widespread reduction or suspension in the use of corticosteroid injections in musculoskeletal services across the United Kingdom (Amani et al., 2020; Little et al., 2020) . Current multi-professional guidance advocates the judicious use of corticosteroid injections within a shared decision making framework (British Orthopaedic Association, 2020) . This requires clinicians and patients to make decisions based upon the best available evidence regarding the risks and benefits of corticosteroid injections including the possibility of systemic immunosuppression (Elwyn et al., 2010) . This narrative review is designed to summarise the current evidence regarding the potential systemic immunosuppressive effects of peripheral intra-articular and soft tissue corticosteroid injections in order to provide a pragmatic guide for healthcare professionals. This is intended to promote shared decision making, facilitate informed consent, and inform risk management related to the use of peripheral musculoskeletal corticosteroid injections in the context of the ongoing COVID-19 pandemic. The innate immune response is the body's rapid but non-specific first line of defence against all invading pathogens including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Innate immune processes are activated within a few hours of viral infection and play a critical role in preventing the initial stages of infection and slowing or inhibiting viral replication and transfer between cells (Sette & Crotty, 2021) . Innate immune cells employ various complicated pathways and pattern recognition molecules to detect invading viruses. This triggers the release of messengers known as cytokines. Cytokines have numerous functions at multiple stages of the immune response. There are two types of interferon (IFN) induced upon viral infection (Samuel, 2001) . Type one IFNs are secreted from infected cells and include IFNα and IFNβ (McNab et al., 2015) . Their functions include induction of cell-intrinsic antiviral states in infected and neighbouring cells which limits the spread of viruses. They also support antigen presentation and activation of the adaptive immune response and promote Natural Killer (NK) cell functions whilst restraining pro-inflammatory pathways and cytokine production (Ivashkiv & Donlin, 2014) . NK cells are a type of lymphoid cell that play an essential role in the innate immune response against viral infections. They express both inhibitory and activating or stimulatory receptors that regulate their cytotoxicity. Hence, NK cells are able to kill virally infected and stressed cells via various pathways (Cerwenka & Lanier, 2001; Duev-Cohen et al., 2016; Glasner et al., 2012) . Recent studies demonstrate a reduction in NK cell cytotoxicity in severe COVID-19 (Wilk et al., 2020; Zheng et al., 2020) . Type two IFNs include IFNγ which is mainly produced by T lymphocytes and NK cells (McNab et al., 2015) . IFNγ activates innate responses by augmenting inflammatory cytokine and chemokine production, microbial killing by phagocytic monocytes such as macrophages, and antigen presentation by dendritic cells (Hu & Ivashkiv, 2009 ). Other important cytokines, include tumour necrosis factor alpha (TNF-α) and interleukins (IL), particularly IL-1, IL-6 and IL-18. Together they induce antiviral programs in target cells and potentiate the adaptive immune response (Vabret et al., 2020) . Cytokines present a major barrier to viral infection and replication. Consequently many viruses including SARS-CoV-2 have evolved various complex mechanisms to evade and inhibit induction and signalling of IFNs and other cytokines (Vabret et al., 2020; Cameron et al., 2012; Blanco-Melo et al., 2020) . The adaptive immune response is slower but more sophisticated than the innate immune response and is specific to the invading pathogen. It can take up to 6-20 days after priming to generate sufficient adaptive immune cell numbers to control viral infections such as COVID-19 (Sette & Crotty, 2021) . Adaptive immune mechanisms are primarily responsible for viral clearance and elimination. T lymphocytes play a pivotal role in the adaptive immune response to viral infections. CD4 T lymphocytes orchestrate the response of other immune cells and provide B lymphocytes with the required help to produce immunoglobulins (antibodies) which help neutralise viruses. CD8 T lymphocytes kill virally infected cells to reduce the burden and spread of viruses. In response to SARS-CoV-2 infection both CD4 and CD8 T lymphocytes have been found to be reduced in patients with moderate and severe COVID-19 (Blanco-Melo et al., 2020; Chen et al., 2020; Diao et al., 2020; Liu et al., 2020; Zhou et al., 2020) . This is most notable with respect to CD8 T lymphocytes in patients with severe COVID-19 that required admission to intensive care, which may correlate with COVID-19-associated disease severity and mortality (Wang et al., 2021) . Prolonged use of oral corticosteroids affects both the innate and adaptive immune responses to infection (Pivonello et al., 2016) . All the main components of the innate immune response are reduced including NK cells cytotoxic action on virally infected cells as well as other phagocytic and antigen-presenting monocytes and granulocytes (Guarnotta et al., 2020) . Similar effects have been described in relation to the adaptive immune response (Strehl et al., 2019) . The body's endogenous glucocorticoid (cortisol) plays an essential but not fully understood role in modulating the immune system via the hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is activated by inflammatory stimuli that release pro-inflammatory cytokines such as IL-1b and TNFα. This causes the release of cortisol which prevents further production of pro-inflammatory cytokines and thus exerts an anti-inflammatory effect. Continuous HPA axis activation following exogenous oral corticosteroid administration can lead to suppression of immune responses (McEwen et al., 1997; Sapolsky et al., 2000) . Hypophysectomised animals (those with the pituitary gland surgically removed) have been shown to have impaired innate and adaptive immune responses (Gala, 1991) . In such cases the function of the immune system can be restored following replacement of either prolactin and/or growth hormone (endogenous hormones produced by the anterior pituitary) demonstrating the pivotal role the HPA axis plays in immune function (Gala, 1991) . There are numerous studies investigating the effect of peripheral corticosteroid injections on HPA axis function. A detailed summary of these can be found in Table 1 et al., 1997; Sapolsky et al., 2000) and hypophysectomy (Gala, 1991) on HPA axis and immunological function, a significant immunosuppressive effect cannot be excluded. HPA suppression following oral corticosteroids is associated with a variety of patient related risk factors including diabetes, depression, smoking, age, race and body mass index (Manson et al., 2009; Olivarius et al., 2011) . Currently, there is no comparable evidence to support similar identifiable risk factors in relation to injected corticosteroid. There are currently two studies investigating the possibility of increased COVID-19 infection risk following corticosteroid injection. vaccines that use viral mRNA to provide the genetic code to allow host cells to produce the SARS-CoV-2 viral spike protein (Amanat & Krammer, 2020; Pardi et al., 2018) . The Oxford-AstraZeneca vaccine uses a replication deficient chimpanzee adenovirus vector to deliver the DNA sequence that codes for the SARS-CoV-2 viral spike protein to allow host cells to produce the viral spike protein (Van Doremalen et al., 2020) . Production of the viral spike protein provides intracellular antigens that are subsequently expressed by antigen presenting cells (innate immune response) to activate T and B lymphocytes (adaptive immune response). Activation of T and B lymphocytes provides long term immune memory (Ewer et al., 2021; Sahin et al., 2020) . This facilitates a quicker and more effective immune response if an individual is subsequently exposed to SARS-CoV-2 infection. There begin to return to normal at around day 20 (Poland et al., 2020; Thevarajan et al., 2020; Xu et al., 2020) . IgM antibodies peak 10-12 days after symptom onset and start to reduce from day 18, whereas IgA antibodies peak after 20-22 days (Padoan et al., 2020) . IgG antibodies are detectable 10 days after symptom onset and increase for the first 3 weeks before beginning to decrease after 8 weeks (Poland et al., 2020) . Evidence from vaccine efficacy trials suggests that participants gain a substantial degree of immunity within 2-3 weeks following a single vaccination dose. The Pfizer- Clinicians are required to discuss the risks and benefits of treatments with patients to promote shared decision making and obtain informed consent (Turnham et al., 2020) . The risks of administering a corticosteroid injection to an asymptomatic or pre-symptomatic individual with COVID-19 and the potential risks of nosocomial infection attending for an injection are currently unknown and likely to vary over time and between individuals (Bryan et al., 2020; Sokol & Dattani, 2020; Turnham et al., 2020) In such circumstances clinicians are obliged to discuss the potential risks including the inherent un- -7 The evidence presented in this review provides clinicians with a pragmatic guide to risk management. The potential immunosuppressive risks of corticosteroid injection may be mitigated to some extent by the choice of preparation, dose, number of injections performed simultaneously, and interval between injections. A review of the current evidence regarding risk management can be found in Influence of intraarticular corticosteroid administration on serum cytokines in rheumatoid arthritis SARS-CoV-2 vaccines: Status report. Immunity Steroid injections & COVID-19: Are specialists justified in defying the guidelines? International Serum methylprednisolone levels following intra-articular injection of methylprednisolone acetate A thermographic and clinical comparison of three intra-articular steroid preparations in rheumatoid arthritis Imbalanced host response to SARS-CoV-2 drives development of COVID-19 Management of patients with musculoskeletal and rheumatic conditions who are on corticosteroids, require initiation of oral/IV corticosteroids, require a corticosteroid injection The safety of corticosteroid injections during the COVID-19 global pandemic Unknown unknowns: Surgical consent during the COVID-19 pandemic Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model Natural killer cells, viruses and cancer Symptomatic COVID-19 infections in outpatient image-guided corticosteroid injection patients during the lockdown phase Clinical and immunological features of severe and moderate coronavirus disease 2019 Injectable corticosteroids in modern practice Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) High risk of adrenal insufficiency after a single articular steroid injection in athletes The human 2B4 and NTB-A receptors bind the influenza viral hemagglutinin and co-stimulate NK cell cytotoxicity Implementing shared decision making in the NHS Adrenocortical function and responsiveness to tetracosactrin infusions after intra-articular treatment with triamcinolone acetonide and hydrocortisone acetate Faculty of Pain Medicine of the Royal College of Anaesthetists. (2020). FPM response to concern related to the safety of steroids injected as part of pain procedures during the current COVID-19 virus pandemic Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: A randomized controlled study Prolactin and growth hormone in the regulation of the immune system Decision making and consent Elucidating the mechanisms of influenza virus recognition by Ncr1 Glucocorticoid excess and COVID-19 disease The effect of intra-articular injection of betamethasone acetate/betamethasone sodium phosphate at the knee joint on the hypothalamic-pituitaryadrenal axis Intra-articular methylprednisolone acetate injection at the knee joint and the hypothalamic-pituitary-adrenal axis: A randomized controlled study Simultaneous bilateral knee injection of methylprednisolone acetate and the hypothalamic pituitary−adrenal axis: A single blind case control study Adverse events of low-to medium-dose oral glucocorticoids in inflammatory diseases: A meta-analysis Cross-regulation of signalling pathways by interferon-gamma: Implications for immune responses and autoimmune diseases Regulation of type I interferon responses Infection in hip arthroplasty after previous injection of steroid Reduction of cortisol levels after single intra-articular and intramuscular steroid injection COVID-19: A rethink of corticosteroid injection? Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 Evaluation of the pituitaryadrenal axis function following single intraarticular injection of methylprednisolone The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use Systematic review: The safety of intra-articular corticosteroid injection prior to total knee arthroplasty The role of adrenocorticoids as modulators of immune function in health and disease: Neural, endocrine and immune interactions Recent intraarticular steroid injection may increase infection rates in primary THA Corticosteroid injections during the COVID-19 pandemic Type I interferons in infectious disease Specialty guides for patient management during the coronavirus Pandemic, Clinical guide for the management of patients with musculoskeletal and rheumatic conditions on corticosteroids during the coronavirus pandemic Patients newly diagnosed with clinical type 2 diabetes during oral glucocorticoid treatment and observed for 14 years: All-cause mortality and clinical developments IgA-ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study mRNA vaccines-A new era in vaccinology Complications of Cushing's syndrome: State of the art SARS-CoV-2 immunity: Review and applications to phase 3 vaccine candidates COVID-19 SARS-CoV-2 Greenbook chapter 14a Public Health England -Report to JCVI on estimated efficacy of a single dose of Pfizer BioNTech (BNT162b2 mRNA) vaccine and of a single dose of ChAdOx1 vaccine (AZD1222) Tool 5: Consent to treatment, while COVID-19 is present in society COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses Antiviral actions of interferons How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions Adaptive immunity to SARS-CoV-2 and COVID-19 How should surgeons obtain consent during the COVID-19 pandemic? Altered leucocyte trafficking and suppressed tumour necrosis factor α release from peripheral blood monocytes after intra-articular glucocorticoid treatment Glucocorticoids-All-rounders tackling the versatile players of the immune system Risk of infectious complications in patients taking glucocorticosteroids Joint corticosteroid injection associated with increased influenza risk Breadth of concomitant immune responses prior to patient recovery: A case report of nonsevere COVID-19 Consent in the time of COVID-19 Immunology of COVID-19: Current state of the science ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques Effectiveness of first dose of COVID-19 vaccines against hospital admissions in Scotland: National prospective cohort study of 5.4 million people Singledose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials Association between peripheral lymphocyte count and the mortality risk of COVID-19 inpatients Glucocorticoid resorption and influence on the hypothalamic-pituitary-adrenal axis after intra-articular treatment of the knee in resting and mobile patients A single-cell atlas of the peripheral immune response to severe COVID-19 Director-General's opening remarks at the media briefing on COVID19 -March Pathological findings of COVID-19 associated with acute respiratory distress syndrome Infection risk and safety of corticosteroid use. Rheumatic Disease Clinics of North America Functional exhaustion of antiviral lymphocytes in COVID-19 patients Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study The systemic immunosuppressive effects of peripheral corticosteroid injections: A narrative review of the evidence in the context of COVID-19